The Latest Cardiac and Vascular News
– New FlexNav™ delivery system improves control and delivery of the Portico™ TAVI valve even in complex clinical cases – The minimally invasive Portico procedure allows doctors to treat severe aortic valve stenosis without invasive surgery – Approval of the […]
– New Gallant™ high voltage devices offer patients and their doctors a smartphone app and Bluetooth connectivity designed to help doctors tailor therapy to a patient’s unique clinical needs – Gallant ICD and CRT-D devices feature a more comfortable design, […]
ABBOTT PARK, Ill., Feb. 4, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its in-development Fully Implantable Left Ventricular Assist System (FILVAS). The FDA launched the Breakthrough […]
– The CATALYST trial will examine Abbott’s Amplatzer™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation ABBOTT PARK, Ill., Feb. 3, 2020 /PRNewswire/ — Abbott (NYSE: […]
– First-of-its-kind technology addresses critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option – Tendyne valve provides relief from heart failure symptoms and quality-of-life improvement in high-surgical-risk patients – Together with MitraClip™, Tendyne expands […]
– Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent – Fourth-quarter GAAP EPS growth from continuing operations of 59.5 percent and adjusted EPS growth from continuing operations of 17.3 percent – Several businesses achieved double-digit sales […]
GENT, Belgium–(BUSINESS WIRE)–FEops, a leader in personalized predictive planning for structural heart interventions, is proud to announce that today the first patient has been enrolled in the physician-initiated PREDICT-LAA trial. The trial is led by Righshospitalet (Copenhagen, Denmark) and aims to assess whether the use […]
– New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population – If successful, the REPAIR MR study has potential to expand MitraClip’s current indication (patients at […]
– For people battling advanced heart failure, Abbott’s HeartMate 3 heart pump can now be implanted through an incision in the chest wall versus open heart surgery – New, less invasive technique provides cardiac surgeons with the ability to choose […]
– Mr. White will remain Executive Chairman of the Board – Mr. Ford has been elected to the Abbott Board ABBOTT PARK, Ill., Nov. 13, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced that Miles D. White will be stepping down as Chief Executive Officer […]
